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Atorvastatin, a chemical ([R-(R*, R*)]-2-(4-fluorophenyl)-b,d-
dihydroxy-5-(1-methylethyl)-3-phenyl-4-
[(phenylamino)carbonyl]1 H-pyrole-1-heptanoic acid), is a
synthetic HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A)
reductase inhibitor. It has been shown to be remarkably effi-
cacious in decreasing the level of cholesterol and triglyceride
[1]. In order to quantify the level of atorvastatin in plasma, it
needs a sensitive, rapid and selective method. As per the lit-
erature, several LC–MS/MS methods have been reported for the
determination of atorvastatin in human plasma [2].
This research developed a method to quantify atorvastatin
in human plasma. Simvastatin was used as internal stan-
dard. Atorvastatin and simvastatin were extracted by liquid–
liquid extraction using ethyl acetate.The analytical separation
was performed using Acquity® UPLC BEH C18, 100 × 2.1 mm,
1.7 μm.The mobile phase used gradient elution of 0.2% formic
acid in acetonitrile, with flow rate of 0.3 mL/min. The analy-
sis was carried out by multiple reaction monitoring (MRM) in
positive mode using precursor to product combination of m/z
559.05 > 440 for atorvastatin and m/z 419.15 > 199.05 for
simvastatin. The method had a chromatographic run time of
5 minutes and linear calibration curve over the range of 0.2–
100 ng/mL with a correlation coefficient (r) of 0.9998. All the
validation parameters fulfilled the criteria [3] and the method
can be successfully applied for pilot bioequivalence studies of
three formulations of atorvastatin.
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